Literature DB >> 9283776

Treatment of diabetic ketoacidosis using normalization of blood 3-hydroxybutyrate concentration as the endpoint of emergency management. A randomized controlled study.

M I Wiggam1, M J O'Kane, R Harper, A B Atkinson, D R Hadden, E R Trimble, P M Bell.   

Abstract

OBJECTIVE: To compare the efficacy of an extended insulin regimen using correction of hyperketonemia as endpoint with a more conventional regimen in the treatment of diabetic ketoacidosis. RESEARCH DESIGN AND METHODS: A total of 22 patients admitted to a Belfast teaching hospital with clinical and biochemical features of diabetic ketoacidosis (pH < 7.25 and/or bicarbonate < 16 mmol/l) were randomized to either conventional or extended insulin regimens. In the conventional regimen, insulin was administered at 5 U/h until near-normoglycemia (blood glucose < or = 10 mmol/l) and then administered at a reduced rate until clinical recovery. In the extended regimen, administration of insulin at 5 U/h was continued beyond attainment of normoglycemia, until resolution of hyperketonemia (3-hydroxybutyrate < 0.5 mmol/l). Main outcome measures were 3-hydroxybutyrate and bicarbonate levels during the 24 h after attainment of near-normoglycemia.
RESULTS: After near-normoglycemia, correction of hyperketonemia was achieved earlier with the extended treatment (5.9 +/- 0.8 vs. 21.8 +/- 3.4 h, P = 0.0004 [mean +/- SD]). The area under the curve of 3-hydroxybutyrate against time for 24 h after near-normoglycemia was reduced with the extended treatment (24.9 +/- 3.8 vs. 55.9 +/- 6.7 mmol.l-1.h-1, P = 0.001). These differences remained statistically significant after adjustment for higher baseline levels of 3-hydroxybutyrate at near-normoglycemia in the extended treatment group. Bicarbonate levels at 6 and 12 h after near-normoglycemia were not significantly different between groups.
CONCLUSIONS: The extended insulin regimen, which was easy to implement at ward level, produced a more rapid resolution of ketosis than the conventional regimen.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9283776     DOI: 10.2337/diacare.20.9.1347

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  9 in total

1.  The diagnosis of diabetic acute complications using the glucose-ketone meter in outpatients at endocrinology department.

Authors:  Xu Cao; Xuejue Zhang; Yang Xian; Jichuan Wu; Mingjing Bao; Yan Yang; Xianjun Zhu; Lei Zhang; Limei Liu; Yi Yang; Hui Zhou; Pengqiu Li
Journal:  Int J Clin Exp Med       Date:  2014-12-15

2.  Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus.

Authors:  David B Sacks; Mark Arnold; George L Bakris; David E Bruns; Andrea Rita Horvath; M Sue Kirkman; Ake Lernmark; Boyd E Metzger; David M Nathan
Journal:  Diabetes Care       Date:  2011-06       Impact factor: 19.112

3.  Influence of hematocrit, blood gas tensions, and pH on pressure-flow relations in the isolated canine lung.

Authors:  D Bucens; M C Pain
Journal:  Circ Res       Date:  1975-11       Impact factor: 17.367

Review 4.  Diagnosis and treatment of diabetic ketoacidosis and the hyperglycemic hyperosmolar state.

Authors:  Jean-Louis Chiasson; Nahla Aris-Jilwan; Raphaël Bélanger; Sylvie Bertrand; Hugues Beauregard; Jean-Marie Ekoé; Hélène Fournier; Jana Havrankova
Journal:  CMAJ       Date:  2003-04-01       Impact factor: 8.262

5.  PHACOS, a functionalized bacterial polyester with bactericidal activity against methicillin-resistant Staphylococcus aureus.

Authors:  Nina Dinjaski; Mar Fernández-Gutiérrez; Shivaram Selvam; Francisco J Parra-Ruiz; Susan M Lehman; Julio San Román; Ernesto García; José L García; Andrés J García; María Auxiliadora Prieto
Journal:  Biomaterials       Date:  2013-10-04       Impact factor: 12.479

6.  Controversies Around the Measurement of Blood Ketones to Diagnose and Manage Diabetic Ketoacidosis.

Authors:  Eric S Kilpatrick; Alexandra E Butler; Linda Ostlundh; Stephen L Atkin; David B Sacks
Journal:  Diabetes Care       Date:  2022-02-01       Impact factor: 19.112

7.  Multicenter, Open-Label, 2-Arm, Pilot Trial for Safe Reduction of Basal Insulin Dose Combined with SGLT2 Inhibitor in Type 1 Diabetes Mellitus: Study Protocol for a RISING-STAR Trial.

Authors:  Masahide Hamaguchi; Yoshitaka Hashimoto; Toru Tanaka; Goji Hasegawa; Michiyo Ishii; Hiroshi Okada; Kazuteru Mitsuhashi; Noriyuki Kitagawa; Emi Ushigome; Masahiro Yamazaki; Michiaki Fukui
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2021-09-27

8.  Relapse of diabetic ketoacidosis secondary to insulin pump malfunction diagnosed by capillary blood 3-hydroxybutyrate: a case report.

Authors:  John Scott Baird
Journal:  Cases J       Date:  2009-08-05

Review 9.  Smart polyhydroxyalkanoate nanobeads by protein based functionalization.

Authors:  Nina Dinjaski; M Auxiliadora Prieto
Journal:  Nanomedicine       Date:  2015-02-24       Impact factor: 5.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.